Levi & Korsinsky, LLP: Chronology of Events in the Inovio Pharmaceuticals Securities Class Action

Key Dates and Disclosure Events Shareholders Need to Know

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP encourages investors who suffered losses in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) to contact the firm.

WHO IS AFFECTED: Those who purchased Inovio securities between October 10, 2023 and December 26, 2025 may be entitled to recover damages.

Chronology of Material Events

October 10, 2023 — Class Period Begins
The complaint recounts that Inovio issued a press release announcing FDA feedback that data from its Phase 1/2 trial could support a BLA submission under the accelerated approval program.

January 3, 2024 — BLA Submission Timeline Announced
As detailed in the action, the Company announced plans to submit the BLA in the second half of 2024, allegedly following "productive discussions with the FDA."

August 8, 2024 — Manufacturing Issue Disclosed
The lawsuit chronicles that Inovio revealed a manufacturing issue with the CELLECTRA device component, allegedly causing a delay to mid-2025 for BLA submission.

December 29, 2025 — FDA Review Classification Revealed
The complaint recounts that Inovio announced the FDA accepted its BLA on a standard rather than accelerated review timeline, allegedly indicating insufficient information for accelerated approval eligibility.

Timeline of Alleged Disclosure Failures

• October 2023: Management allegedly assured investors of accelerated approval pathway
• January-May 2024: The lawsuit chronicles repeated assurances of second-half 2024 BLA submission
• August 2024: As detailed in the action, manufacturing issues first disclosed, delaying timeline
• November 2025: The complaint recounts BLA submission completed, seeking accelerated approval
• December 2025: FDA allegedly accepted BLA on standard review, not accelerated

"Timely disclosure of material developments is fundamental to fair and efficient markets," stated Joseph E. Levi, Esq. "We encourage shareholders to learn about their rights under the federal securities laws."

Join this investigation or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.

ABOUT THE FIRM

For over two decades, Levi & Korsinsky, LLP has represented shareholders in securities class actions. The firm has ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years. Those wishing to serve as lead plaintiff must act by April 7, 2026.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.